# Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

> **NCT00003269** · PHASE2 · COMPLETED · sponsor: **Scripps Health** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer
- Drug/Agent Toxicity by Tissue/Organ
- Lung Cancer
- Lymphoma
- Ovarian Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** amifostine trihydrate
- **DRUG:** cisplatin
- **DRUG:** cyclophosphamide
- **DRUG:** etoposide

## Key facts

- **NCT ID:** NCT00003269
- **Lead sponsor:** Scripps Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-02
- **Primary completion:** 2001-01
- **Final completion:** 2001-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003269, "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00003269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*